

RANBAXY LABORATORIES LIMITED
Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2012
(Rupees in millions, except for share data, and if otherwise stated)

PART I

Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		Quarter ended 30 June 2012	Quarter ended 31 March 2012	Quarter ended 30 June 2011	Six months ended 30 June 2012	Six months ended 30 June 2011	Year ended 31 December 2011
1	Income from operations						
	(a) Sales						
	- Within India (net of excise duty)	5,612.24	5,045.10	4,950.79	10,657.34	9,381.26	19,762.42
	- Outside India (refer to note 1)	9,115.26	13,057.18	7,459.55	22,172.44	13,573.53	54,996.54
	Net sales (net of excise duty)	14,727.50	18,102.28	12,410.34	32,829.78	22,954.79	74,758.96
	(b) Other operating income (refer to note 2)	531.48	562.44	451.91	1,093.92	916.34	2,381.68
	Total income from operations (net)	15,258.98	18,664.72	12,862.25	33,923.70	23,871.13	77,140.64
2	Expenses						
	(a) Cost of materials consumed	3,806.21	3,705.34	4,629.72	7,511.55	9,371.53	17,836.60
	(b) Purchases of stock-in-trade	2,152.94	1,940.02	1,457.64	4,092.96	2,759.22	6,367.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(182.53)	109.44	(662.33)	(73.09)	(1,531.34)	(1,357.22)
	(d) Employee benefits expense (refer to note 5)	2,531.68	2,516.28	2,272.16	5,047.96	4,539.49	8,607.10
	(e) Depreciation, amortisation and impairment expense	485.34	468.73	469.78	954.07	932.39	2,740.83
	(f) Other expenses (refer to note 7)	5,679.26	6,767.67	4,389.55	12,446.93	8,424.29	32,750.76
	(g) Foreign exchange loss/ (gain) others, net	3,027.87	(1,299.50)	(136.54)	1,728.37	(401.27)	1,106.58
	Total expenses	17,500.77	14,207.98	12,419.98	31,708.75	24,094.31	68,051.96
3	(Loss)/ profit from operations before other income, finance costs and exceptional items (1-2)	(2,241.79)	4,456.74	442.27	2,214.95	(223.18)	9,088.68
4	Other income	610.88	536.91	121.21	1,147.79	613.14	1,111.33
5	(Loss)/ profit from ordinary activities before finance costs and exceptional items (3+4)	(1,630.91)	4,993.65	563.48	3,362.74	389.96	10,200.01
6	Finance costs (refer to note 11)	1,632.23	168.50	232.42	1,800.73	609.27	2,963.86
7	(Loss)/ profit from ordinary activities after finance costs but before exceptional items (5-6)	(3,263.14)	4,825.15	331.06	1,562.01	(219.31)	7,236.15
8	Exceptional items						
	- Settlement provision (refer to note 3a)	-	-	-	-	-	(26,480.00)
	- (Loss)/ gain on foreign currency option derivatives, net (other than loans) (refer to note 3b)	(5,993.52)	3,447.16	1,117.94	(2,546.36)	1,137.78	(11,242.85)
9	(Loss)/ profit from ordinary activities before tax (7+8)	(9,256.66)	8,272.31	1,449.00	(984.35)	918.47	(30,486.70)
10	Tax expense, net	-	-	(54.75)	-	(56.21)	33.79
11	Net (loss)/ profit for the period (9-10)	(9,256.66)	8,272.31	1,503.75	(984.35)	974.68	(30,520.49)
12	Paid - up equity share capital (Face value of Rs. 5 each)	2,110.56	2,110.16	2,106.82	2,110.56	2,106.82	2,110.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						17,131.64
14	(Loss)/ earnings per share (Rs.) - not annualised						
	Basic	(21.95)	19.62	3.57	(2.33)	2.31	(72.42)
	Diluted	(21.95)	19.58	3.55	(2.33)	2.30	(72.42)

See accompanying notes to the standalone unaudited financial results

PART II

Select information for the quarter and six months ended 30 June 2012							
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		Quarter ended 30 June 2012	Quarter ended 31 March 2012	Quarter ended 30 June 2011	Six months ended 30 June 2012	Six months ended 30 June 2011	Year ended 31 December 2011
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding #						
	- Number of shares	145,005,743	144,707,624	145,468,296	145,005,743	145,468,296	145,827,559
	- Percentage of shareholding	34.35%	34.29%	34.52%	34.35%	34.52%	34.56%
2	Promoters and Promoter Group Shareholding						
a)	Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
b)	Non - encumbered						
	- Number of shares	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	63.66%	63.67%	63.77%	63.66%	63.77%	63.68%

Aggregate public shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters and Promoter Group Shareholding and Global Depository Shares)

Particulars		(Unaudited)
		Quarter ended 30 June 2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	7
	Disposed off during the quarter	7
	Remaining unresolved at the end of the quarter	Nil

Handwritten signature

RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2012

(Rupees in millions, except for share data, and if otherwise stated)

Notes:

- 1 Sales outside India for all periods presented include significant sales relating to First-To-File (FTF) products in the United States of America ("USA"). Further, pursuant to the accounting policy followed by the Company, sales outside India for all periods presented includes transfer pricing adjustments with its subsidiaries for materials already supplied to them (including supplied in earlier periods) determined on the basis of significant judgement and estimates. Further, Sales outside India for the quarter ended 30 June 2012 is net of Rs. 252.46 representing prior period reversal of sales due to transfer pricing adjustment.
- 2 Other operating income for the quarter and six months ended 30 June 2012 includes prior period milestone income amounting to Rs. 55.42.
- 3 a) On 20 December 2011, the Company agreed to enter into a Consent Decree with the Food and Drug Administration ("FDA") of United States of America ("USA") as a step towards resolving the existing administrative actions taken by the FDA against the Company's Paonta Sahib and Dewas facilities. The Consent Decree was approved by the United States District Court for the District of Maryland on 26 January 2012 and went into effect on the same date. The Consent Decree establishes certain requirements intended to further strengthen the Company's procedures for ensuring the integrity of data in its US applications and good manufacturing practices at its Paonta Sahib and Dewas facilities. Successful compliance with the terms of the Consent Decree is required for the Company to resume supply of products from the Dewas and Paonta Sahib facilities to the USA.

Further, the Company is negotiating towards a settlement with the Department of Justice ("DOJ") of the USA for resolution of potential civil and criminal allegations by DOJ. Accordingly, the Company had recorded a provision of Rs. 26,480 (USD 500 million) in the year ended 31 December 2011, which the Company believes will be sufficient to resolve all potential civil and criminal liability.
Any gain/ loss on account of changes in exchange rate and related interest expense is presented in the relevant line item.
- b) The amount represents foreign exchange gain/ (loss), net, on foreign currency option derivatives taken during previous years (other than option derivatives relating to loans) which are accounted in accordance with Accounting Standard 30, "Financial Instruments: Recognition and Measurement".
- 4 Standalone Statement of Assets and Liabilities are given below:

Particulars	(Unaudited)	(Audited)
	As at 30 June	As at 31 December
	2012	2011
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
a) Share capital	2,110.56	2,110.00
b) Reserves and surplus	16,863.61	17,131.64
c) Money received against share warrants	-	-
Sub-total - Shareholders' funds	18,974.17	19,241.64
2 Share application money pending allotment	41.19	6.66
3 Non-current liabilities		
a) Long-term borrowings	9,487.60	9,524.11
b) Deferred tax liabilities (net)	-	-
c) Other long-term liabilities	15,239.40	15,977.19
d) Long-term provisions	2,583.67	2,297.92
Sub-total - Non-current liabilities	27,310.67	27,799.22
4 Current liabilities		
a) Short-term borrowings	29,861.20	29,310.02
b) Trade payables	8,718.05	10,026.83
c) Other current liabilities	17,094.94	29,929.99
d) Short-term provisions	28,198.52	26,953.60
Sub-total - Current liabilities	83,872.71	96,220.44
TOTAL EQUITY AND LIABILITIES	130,198.74	143,267.96
B ASSETS		
1 Non-current assets		
a) Fixed assets	21,120.59	20,761.21
b) Non-current investments	32,321.21	34,081.47
c) Deferred tax assets (net)	-	-
d) Long-term loans and advances	11,232.07	9,363.90
e) Other non-current assets	0.86	0.86
Sub-total - Non-current assets	64,674.73	64,207.44
2 Current assets		
a) Current investments	21.63	26.46
b) Inventories	16,852.91	16,552.31
c) Trade receivables	13,022.23	36,828.19
d) Cash and cash equivalents (refer to note 10)	29,805.22	19,379.53
e) Short-term loans and advances	3,424.26	3,519.45
f) Other current assets	2,397.76	2,754.58
Sub-total - Current assets	65,524.01	79,060.52
TOTAL ASSETS	130,198.74	143,267.96

(Handwritten signature)

RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2012

(Rupees in millions, except for share data, and if otherwise stated)

Notes:

5 The managerial remuneration paid by the Company to Mr. Arun Sawhney (CEO and Managing Director) during the year ended 31 December 2011 exceeded the limits specified in relevant provisions of the Companies Act, 1956 ("the Act") by Rs. 47.55. The Shareholders, at their Annual General Meeting ("AGM") held on 8 May 2012, approved the waiver of recovery of such excess remuneration. The Company would seek requisite approvals as may be required for excess remuneration paid. This has a reference to the qualification made in the audit report for the year ended 31 December 2011, and in the review reports for the quarter ended 31 March 2012 and quarter and six months ended 30 June 2012.

The Shareholders at the AGM held on 8 May 2012 had approved re-appointment of Mr. Arun Sawhney as CEO and Managing Director for a period of five years and payment of remuneration to him for a period of three years w.e.f. 1 January 2012. Accordingly, during the quarter ended 31 March 2012 and 30 June 2012, the Company had recorded an expense of Rs. 29.71 and Rs. 30.08 as managerial remuneration. The limits for the managerial remuneration for the year ending 31 December 2012 will be determined as at the year end. Accordingly, the Company, if required, will also take necessary steps to seek requisite approvals in this regard.

6 The research and development expenses is classified under respective heads of total expenses according to the nature of expense. The aggregate amount of such expenses (excluding depreciation, amortisation and impairment) for all periods presented is set out below:

Particulars	(Unaudited) Quarter ended 30 June	(Unaudited) Quarter ended 31 March	(Unaudited) Quarter ended 30 June	(Unaudited) Six months ended 30 June	(Unaudited) Six months ended 30 June	(Audited) Year ended 31 December
	2012	2012	2011	2012	2011	2011
Research and development expenses	1,156.31	1,017.09	1,214.59	2,173.40	2,244.05	4,529.22

7 The Company has accrued an expense as claims and contractual payment towards a portion of profit payable to another party in relation to sales of a product. Claims and contractual payment expense included in 'Other expenses' qualifies for a separate line item disclosure in accordance with clause 41 of the Listing Agreement as the same is more than 10% of total expenses for the quarter ended 31 March 2012 and year ended 31 December 2011. However, the same has not been disclosed as a separate line item in view of certain terms of agreement with the party. This has a reference to the qualification made in the audit report for the year ended 31 December 2011, and in the review reports for the quarter ended 31 March 2012 and quarter and six months ended 30 June 2012.

8 On exercise of Employees Stock Options, 152,361 equity shares have been allotted on 11 July 2012. The total number of Employees Stock Options outstanding as at 30 June 2012 were 7,333,490, out of which 4,641,862 have vested. The entitlement of shares on exercise of stock options granted on or before 3 October 2002 would increase in the proportion of 3:5, keeping in view the issue of bonus shares on 11 October 2002.

9 The Company's business activity falls within a single primary business segment viz. 'Pharmaceutical'.

10 Cash and cash equivalents as at 30 June 2012 includes Rs. 21,186.38 (Rs.11,515.62 as at 31 December 2011) represented by "other bank balances" which are due for realisation within twelve months from the reporting date.


11 Finance cost includes exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs. The aggregate amount of such exchange difference for all periods presented is set out below.

Particulars	(Unaudited) Quarter ended 30 June	(Unaudited) Quarter ended 31 March	(Unaudited) Quarter ended 30 June	(Unaudited) Six months ended 30 June	(Unaudited) Six months ended 30 June	(Audited) Year ended 31 December
	2012	2012	2011	2012	2011	2011
Foreign exchange loss/(gain)	1,165.41	-190.28	84.15	975.13	332.87	2,269.51

12 Pursuant to amendments made to the Listing Agreement in respect of format of disclosure of financial results, the standalone unaudited financial results for the quarter and six months ended 30 June 2012 has been prepared in the revised format. Accordingly, the previous year/periods figures have also been reclassified to conform to the current period's classification.

13 The above results were reviewed by the Audit Committee on 8 August 2012, and approved by the Board of Directors at their meeting held on 9 August 2012 and have undergone a "Limited Review" by the Statutory Auditors of the Company. The review report of the Statutory Auditors containing the reservations is being filed with the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited and is also available on the Company's website at www.ranbaxy.com.

By order of the Board



Arun Sawhney
CEO and Managing Director

Place: Johannesburg
Date: 9 August 2012

Regd. Office : A-41, Industrial Area Phase VIII A, Sahibzada Ajit Singh Nagar (Mohali) - 160 071 (Punjab)

Website: <http://www.ranbaxy.com>